2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Adjuvant olaparib for 1 year following local treatment and adjuvant/neoadjuvant chemotherapy improved disease-free survival (DFS) in patients with HER2-negative early breast cancer (EBC) with BRCA1 or BRCA2 pathogenic/likely pathogenic variants and high recurrence risk, according to interim results of the multinational, phase III OlympiA study.

The combination of nivolumab–ipilimumab (nivo–ipi) or nivolumab–chemotherapy (nivo–chemo) improved overall survival (OS) compared with chemotherapy alone in the first-line treatment of advanced oesophageal squamous cell carcinoma (ESCC), results of the phase III CheckMate 648 study showed.

Toripalimab added to chemotherapy in the first-line setting delayed disease progression in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC), according to results from the phase III JUPITER-02 trial presented at ASCO 2021.

Adding the anti–PD-1 monoclonal antibodies toripalimab or camrelizumab to first-line standard of care (SoC) with gemcitabine and cisplatin (GC) significantly improves progression-free survival (PFS) vs GC alone in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC), two phase III trials have shown. These results, reported at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021), may position toripalimab or camrelizumab in combination with GC as a new first-line SoC in this patient population.

Treatment with tislelizumab led to a significantly improved overall survival (OS) in patients with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy in the second-line setting, according to the RATIONALE 302* study presented at ASCO 2021.